Vaccinex, Inc. (VCNX)
Largest Insider Buys in Sector
VCNX Stock Price History Chart
VCNX Stock Performance
About Vaccinex, Inc.
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's …
Insider Activity of Vaccinex, Inc.
Over the last 12 months, insiders at Vaccinex, Inc. have bought $1.33M and sold $3,161 worth of Vaccinex, Inc. stock.
On average, over the past 5 years, insiders at Vaccinex, Inc. have bought $5.2M and sold $3,161 worth of stock each year.
Highest buying activity among insiders over the last 12 months: FRIEDBERG ALBERT () — $1.33M. Zauderer Maurice (President and CEO) — $4,865.
The last purchase of 100 shares for transaction amount of $451 was made by FRIEDBERG ALBERT () on 2024‑08‑09.
List of Insider Buy and Sell Transactions, Vaccinex, Inc.
| 2024-08-09 | 100 0.0062% | $4.51 | $451 | +14.19% | ||||
| 2024-08-06 | 2,753 0.1731% | $4.92 | $13,545 | +5.06% | ||||
| 2024-08-05 | 3,653 0.2165% | $4.60 | $16,804 | +5.82% | ||||
| 2024-08-01 | 11,703 0.7174% | $4.72 | $55,238 | +6.69% | ||||
| 2024-07-31 | 200,000 9.6346% | $6.15 | $1.23M | -20.99% | ||||
| 2024-05-30 | 861 0.0604% | $5.20 | $4,473 | +7.88% | ||||
| 2024-05-29 | 957 0.0665% | $4.95 | $4,737 | +11.80% | ||||
| 2024-04-19 | 282 0.0193% | $4.73 | $1,334 | +12.02% | ||||
| 2023-12-26 | Sale | director | 3,149 0.0252% | $0.72 | $2,267 | +660.27% | ||
| 2023-12-08 | Sale | director | 1,334 0.0102% | $0.67 | $894 | +654.66% | ||
| 2023-10-04 | President and CEO | 5,000 0.1036% | $0.97 | $4,865 | +430.85% | |||
| 2023-10-03 | 3M 63.8635% | $1.00 | $3M | +429.26% | ||||
| 2023-10-03 | President and CEO | 505,000 10.7428% | $1.00 | $504,650 | +429.26% | |||
| 2022-02-23 | director | 20,000 0.0523% | $1.32 | $26,360 | -23.08% | |||
| 2022-01-27 | 3.6M 11.2791% | $1.11 | $4M | +15.22% | ||||
| 2022-01-27 | President and CEO | 1.8M 5.6395% | $1.11 | $2M | +15.22% | |||
| 2022-01-27 | director | 90,090 0.282% | $1.11 | $100,000 | +15.22% | |||
| 2020-07-10 | 1.13M 5.0444% | $3.55 | $4M | -35.19% | ||||
| 2020-03-30 | 5,000 0.0316% | $4.06 | $20,300 | -13.18% | ||||
| 2020-03-27 | 4,000 0.0257% | $4.18 | $16,720 | -14.04% |
Insider Historical Profitability
| FRIEDBERG ALBERT | 780624 45.1828% | $3.27 | 29 | 0 | +15.22% | |
| Zauderer Maurice | President and CEO | 22116 1.2801% | $3.27 | 5 | 0 | +15.22% |
| Van Strydonck, Gerald E. | director | 0 0% | $3.27 | 1 | 2 | <0.0001% |
| Frieberg Jacob B. | director | 94510 5.4703% | $3.27 | 2 | 0 | +15.22% |
| Royer Scott E. | Chief Financial Officer | 3999 0.2315% | $3.27 | 4 | 0 |